Request Sample
Request Methodology
Description
Anti Suicide Drugs Market was valued at USD 4 billion in 2021 and expected to reach USD 5.3 billion by 2028 growing at a CAGR of 4% during the forecast period 2022 to 2028. Suicidal behaviour is defined as the preoccupation or act that is focussed on causing one’s own death voluntarily. To have suicidal intent is to have a suicide or deliberate self-killing as one’s purpose. Intent refers to the aim, purpose, or goal of the behaviour. The term indicates a conscious desire or wishes to leave or escape from life, and also suggests a resolve to act. This is contrasted with suicidal motivation, or the driving force behind ideation or intent, which need not be conscious. Development of effective anti-suicidal drugs can be a major breakthrough in reducing the death rate. Currently, non-profit organizations like Stop Suicide, Stop youth suicide and American foundation for suicide prevention are providing social and moral support to the people with suicidal thoughts and tendencies. Increased focus on R&D led to the launch of new range of drugs and a strong pipeline of drugs, which in turn propel the growth of the anti-suicide drugs market. For example, NeuroRX (Acquired by Allergan) completed the phase-II trial for cyclurad (combination of lurasidone and D-Cycloserine, conjugated with ketamine) to treat suicidal tendencies associated with bipolar disorder. Suicide rates are on the rise all across the world, which is one of the market’s primary drivers. Suicides accounted for about 1-1.5 percent of all deaths in 2017, according to the World Health Organization. Rising awareness about excellent mental health, shifting, greater focus on research and development leading to the launch of novel anti-suicidal medications are all factors contributing to the market’s growth.
